Alnylam Pharmaceuticals, Inc. Investigation - ALNY

Company
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Learn more about the Alnylam Pharmaceuticals, Inc. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

Alnylam Pharmaceuticals, Inc. Investigation Details

Alnylam Pharmaceuticals, Inc. shares fell $58.40 per share, or 25.13%, to close at $174.00 on October 29, 2026, after the Company reported its financial results for the third quarter ended September 30, 2026. In those results, the Company reported slowing demand for Amvuttra, one of its treatments for transthyretin-mediated amyloidosis, which accounts for 87.5% of the Company's product sales. The Company reported U.S. total transthyretin demand growth of $81 million for the quarter, compared with $129 million for the preceding quarter. The single-day decline followed the release of those quarterly results and the demand figures disclosed with them. Amvuttra's share of product sales means the reported slowdown in transthyretin demand growth relates to the substantial majority of the Company's product revenue. The investigation concerns whether Alnylam adequately disclosed the slowing demand for Amvuttra and the decline in U.S. total transthyretin demand growth from $129 million in the preceding quarter to $81 million ahead of its October 29, 2026 third quarter results announcement.

Get Started